Supplementary funding to support the extension of the EDCTP-funded PrEPVacc trial

点击翻译按钮获取中文摘要

"Supplementary funding to support the extension of the EDCTP-funded trial ""A combination efficacy study in Africa of two DNA-MVA- or DNA- Env protein HIV-1 vaccine regimens with pre-exposure prophylaxis (PrEPVacc)"" held by Professor Jonathan Weber (Imperial College of Science Technology and Medicine, UK). PrEPVacc is a Phase IIb, three-arm, two-stage HIV efficacy vaccine trial with a second randomisation to compare the newer PrEP drug Descovy to the established standard for PrEP, Truvada (https://www.prepvacc.org/)The supplementary funding will allow follow-up of trial participants and complete analysis of the trial data. "